Ocugen Announces CSO to Present on Modifier Gene Therapy at Retina World Congress
May 02, 2024 07:15 ET
|
Ocugen
MALVERN, Pa., May 02, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Gene Therapies in Degenerative Retinal Disease Hold Potential to Capture Significant Portion of Market
May 01, 2024 14:17 ET
|
Spherix Global Insights
EXTON, PA, May 01, 2024 (GLOBE NEWSWIRE) -- In the landscape of healthcare innovation, retinal disorders, including both inherited and degenerative diseases, have become a leading focus area for...
Atsena Therapeutics Announces Positive Clinical Data from the First Cohort of Phase I/II Trial Evaluating ATSN-201 Gene Therapy for the Treatment of X-linked Retinoschisis (XLRS)
May 01, 2024 07:30 ET
|
Atsena Therapeutics
Subretinal injection of ATSN-201 was well tolerated in all patients in the first cohort with extensive resolution of schisis observed in two patients Provides evidence that AAV.SPR spreads laterally...
Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
April 30, 2024 08:38 ET
|
Fractyl Health, Inc.
Fractyl Health Announces Multiple Presentations at DDW 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
Global Cell & Gene Therapy Cold Chain Logistics Market Outlook, 2024-2029: Surge in Collaborations and Patient-Centric Logistics for Personalized Therapies Driving the Market at 14.1% CAGR
April 30, 2024 04:03 ET
|
Research and Markets
Dublin, April 30, 2024 (GLOBE NEWSWIRE) -- The "Cell & Gene Therapy Cold Chain Logistics Market - Global Industry Size, Share, Trends, Opportunity and Forecast, 2019-2029F" report has been added...
Ocugen Announces OCU400—Modifier Gene Therapy—Phase 1/2 Data Presentation at Retinal Cell and Gene Therapy Innovation Summit 2024
April 29, 2024 06:45 ET
|
Ocugen
MALVERN, Pa., April 29, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
UPDATE -- Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024 09:05 ET
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Global Cell and Gene Therapies in Hemophilia A & B Analysis Report 2024: Market to Reach $2.2 Billion by 2029 - Major Players Are Expected To Intensify Competition
April 26, 2024 07:22 ET
|
Research and Markets
Dublin, April 26, 2024 (GLOBE NEWSWIRE) -- The "Cell and Gene Therapies in Hemophilia A & B" report has been added to ResearchAndMarkets.com's offering. The global hemophilia A and B CGT...
Ocugen to Present on Modifier Gene Therapy Platform at Association for Research in Vision and Ophthalmology 2024 Annual Meeting
April 26, 2024 06:30 ET
|
Ocugen
MALVERN, Pa., April 26, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and...
Adverum Biotechnologies to Present LUNA 26-week Phase 2 Interim Analysis at the ASRS Annual Scientific Meeting
April 25, 2024 16:05 ET
|
Adverum Biotechnologies, Inc.
REDWOOD CITY, Calif., April 25, 2024 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for...